Tolerx, Inc.

Type 2 diabetes isn’t an obvious spot for any aspiring biotech entrepreneur to invest hard-raised dollars. The highly competitive marketplace is dominated by Sanofi , desperate as $7 billion Lantu

After a competitive bidding process, MorphoSys AG has struck a development and commercialization deal with GlaxoSmithKline PLC for its mid-stage rheumatoid arthritis antibody. The German compa

Andromeda Biotech has released top-line results for its lead product, DiaPep277, that suggest it could prove an effective immunotherapeutic product for patients with newly diagnosed type 1 diabetes. T

Autoimmune treatments in type 1 diabetes hold forth the promise of preserving the body’s own insulin production. However, three late-stage candidates – teplizumab, otelixizumab, and Diamyd – have fail